Cingulate Inc. (CING)

NCM – Real vaqt narxi. Valyuta: USD

4.79

-0.17 (-3.43%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Kompaniya haqida

Cingulate Inc., biofarmatsevtika kompaniyasi, Amerika Qo'shma Shtatlarida diqqat etishmasligi/giperaktivlik buzilishi (DEHB) va tashvishlarni davolash uchun o'zining dori vositalarini yetkazib berish platformasi texnologiyasidan foydalangan holda farmatsevtika mahsulotlarini ishlab chiqadi. Kompaniyaning asosiy mahsulot nomzodi CTx-1301 (deksmetilfenidat) bo'lib, u bolalar, o'smirlar va kattalardagi DEHBni davolash uchun 3-bosqichli klinik sinovlarda. Shuningdek, u tashvishlarni davolash uchun formulasi ishlab chiqilayotgan CTx-2103 (buspiron)ni ishlab chiqadi. Bundan tashqari, kompaniya DEHBni davolash uchun CTx-1302 (dekstroamfetamin) uchun klinik rejasini boshlashni rejalashtirmoqda. Cingulate Inc. 2012-yilda tashkil etilgan va uning shtab-kvartirasi Kanzas-Siti, Kanzasda joylashgan.

Asosiy rahbarlar

Ism	Lavozim
Dr. Matthew N. Brams M.D.	Co-Founder, Executive VP & Chief Medical Officer
Dr. Raul R. Silva M.D.	Co-Founder, Executive VP & Chief Science Officer
Dr. Shane J. Schaffer Pharm.D.	Co-Founder, CEO & Director
Mr. Downey Bryan Wade	Executive VP & Chief Commercial Officer
Mr. Nilay D. Patel J.D.	Executive VP, Chief Legal Officer & Chief Compliance Officer
Mr. Thomas Dalton	Vice President of Investor & Public Relations